amyloidosis

(redirected from AA amyloidosis)
Also found in: Dictionary, Medical, Encyclopedia, Wikipedia.
Related to AA amyloidosis: AL amyloidosis, reactive amyloidosis
  • noun

Words related to amyloidosis

a disorder characterized by deposit of amyloid in organs or tissues

References in periodicals archive ?
Systemic AA amyloidosis is observed in a subset of patients with chronic inflammatory disorders and in a familial form (known as Familial Mediterranean Fever) in which insoluble amyloid deposits accumulate in vital organs (including kidney and liver) leading to organ dysfunction and failure.
51,52) A lack of biopsy improvement after proteinuria resolution in AA amyloidosis also has been reported.
To address this issue, an elegant "overlay technique" has been developed, in which a Congo red stain and immunohistochemistry are performed on the same slide-at least in the case of AA amyloidosis.
Eprodisate (KIACTA(TM)) was investigated in an international, randomized, double-blind, placebo-controlled, and parallel-designed Phase II/III clinical trial in which 183 AA amyloidosis patients were enrolled at 27 sites around the world (Eprodisate for AA Amyloidosis Trial, EFAAT).
Positive staining for serum amyloid A protein by immunohistochemistry confirms the diagnosis of AA amyloidosis (Figure 4, C).
In December 2007, the Company received an acknowledgement from the FDA that Neurochem's response to the approvable letter received in July 2007 for the New Drug Application (NDA) for eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis is a complete, Class 2 response.
received an acknowledgement from the Food and Drug Administration (FDA) that the Company's response to the second approvable letter of July 2007 for the NDA for eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis is a complete, Class 2 response.
NASDAQ: NRMX; TSX: NRM), announces that the New England Journal of Medicine (NEJM) published the results of the "Eprodisate For AA Amyloidosis Trial" (EFAAT), recognized as a landmark clinical trial in the search for a treatment of AA amyloidosis.
Following an approvable letter received by the Company in August 2006, the United States Food and Drug Administration (FDA) is completing its review of Neurochem's New Drug Application for eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis.
Eprodisate (KIACTA(TM); formerly FIBRILLEX(TM)) is currently being developed for the treatment of AA amyloidosis, and is under regulatory review for marketing approval by the U.
Kiacta is an orally bioavailable small molecule that is in a final Phase III confirmatory trial for the treatment of AA amyloidosis.
AA amyloidosis, in contrast, may be associated with chronic inflammatory disorders, and therapy involves control of the underlying condition.
1) A significant association between chronic inflammatory states and fatal AA amyloidosis has also been described in falcons (Falco species) of the Middle East.
In conclusion, this case illustrates a phenotypic shift in a renal transplant patient with unrecognized FMF and secondary AA amyloidosis possibly due to the newly established equilibrium in various cytokines with ongoing immunosuppression.
3) The authors did not describe clearly whether their classification is suitable for this particular form of renal AA amyloidosis.